Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11526 posts found.

BI building at night

FDA approves Boehringer’s Pradaxa reversal agent

October 19, 2015 Sales and Marketing Boehringer Ingelheim, FDA, Pradaxa, Praxbind, anticoagulant, idarucizumab

The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa. The US regulator approved Praxbind (idarucizumab) …
News
Praluent

Sanofi and Regeneron heart drug Praluent available in UK

October 19, 2015 Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent

Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …
News
onglyza

FDA rejects AstraZeneca diabetes combination

October 16, 2015 Research and Development, Sales and Marketing AstraZeneca, FDA, NDA, dapagliflozin, saxagliptin

The FDA has declined to approve AstraZeneca’s New Drug Application (NDA) for the investigational fixed-dose combination of Onglyza and and …
News
pfizer_logo

Pfizer’s Xeljanz denied plaque psoriasis indication by FDA

October 16, 2015 Research and Development, Sales and Marketing FDA, Pfizer, Xeljanj, tofacitinib

The FDA has rejected the indication expansion of Pfizer’s Xeljanz (tofacitinib) for treatment of moderate to severe cases of plaque psoriasis. …
News
abbvies_humira_cost_the_most_to_market_in_the_us_last_month

Top 10 US pharma advertising spenders, September 2015

October 16, 2015 Medical Communications, Sales and Marketing

 As a new study from TV advertising metrics company iSpot reveals the top 40 pharma companies spent $231 million on TV …
Feature
NHS sign

NICE requests more evidence on Duchenne muscular dystrophy therapy

October 16, 2015 Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PCT Therapeutics, Translarna, ataluren

NICE has chosen not to recommend has PTC Therapeutics’ treatment Translarna for Duchenne muscular dystrophy (DMD), asking for further clarification …
News
Valeant logo

Valeant receives court writ over US drug pricing

October 15, 2015 Medical Communications, Sales and Marketing Drug pricing, Isuprel, Nitropress, US, Valeant, subpoena

Valeant Pharmaceuticals has disclosed that it has received two subpoenas in the US, demanding evidence concerning the pricing and distribution …
News
PM David Cameron

ABPI hits back at Prime Minister’s criticism of high drug prices

October 15, 2015 Sales and Marketing ABPI, Drug pricing, Duchenne Muscular Dystrophy, NICE, Translarna, ataluren, david cameron, prime minister, rare disease

The ABPI has responded to comments made by UK Prime Minister David Cameron during yesterday’s Prime Minster’s Questions, in which …
News
WHO flag

Novartis and Biogen launch drug access programmes in developing countries

October 15, 2015 Manufacturing and Production, Sales and Marketing Biogen, Novartis, access, aid, corporate social responsibility, csr, humanitarian aid

Novartis and Biogen have begun new campaigns aimed at increasing access to medicines in developing countries.  The Swiss firm has …
News
vrvb9xyi

Turing faces antitrust probe over Daraprim price hike

October 14, 2015 Sales and Marketing Daraprim, Turing Pharmaceuticals, turing

Turing Pharmaceuticals, the drug company that increased the price of the generic drug Daraprim 50-fold overnight, is facing an antitrust …
News
lars-rebien-soerensen

Novo chief executive ranked ‘world’s best’

October 14, 2015 Medical Communications, Sales and Marketing Harvard Business Review, Lars Rebien Sorensen, Novo Nordisk

Novo Nordisk chief executive Lars Rebien Sørensen has been named the best-performing in the world by the Harvard Business Review. …
Appointment

Merck rebrands as ‘science and technology’ company

October 14, 2015 Medical Communications, Research and Development, Sales and Marketing Merck, Merck Millipore, Merck Serono, rebrand, restructure

Merck Group has rebranded to “reflect its transformation into a science and technology company”, and restructured its business to create …
News
gamidi_cell_logo

Novartis invests further $15m into Gamida Cell

October 13, 2015 Research and Development, Sales and Marketing Gamida Cell, Novartis, pharma mergers and acquisitions

Novartis is to invest an extra $15 million into Israeli stem cell therapy developer Gamida Cell, adding an additional 2.5% …
News
s_oschmann_2015

Stefan Oschmann promoted to top job at Merck KGaA

October 13, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Merck KGaA, Stefan Oschmann

Merck KGaA has announced the promotion of its deputy chief executive, Stefan Oschmann, to the role of chief executive, starting …
Appointment
oma_nice

NICE launches new service to speed NHS adoption of health technologies

October 13, 2015 Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, OMA, market access, office for market access

NICE is introducing a new service, the Office for Market Access (OMA), to work with industry to speed up NHS …
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026